Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.

ABSTRACT:

Objectives

This post hoc analysis of TIOtropium Safety and Performance In Respimat (TIOSPIR) evaluated safety and exacerbation efficacy in patients with stable (≥ 2 months) use of tiotropium HandiHaler 18 µg (HH18) prior to study entry, to evaluate whether there was a difference in risk for patients who switched from HH18 to tiotropium Respimat 2.5 µg (R2.5) or 5 g (R5).

Setting

TIOSPIR (n=17,135) was an international, Phase IIIb/IV, randomised, double-blind, parallel-group, event-driven trial.

Participants

Patients from TIOSPIR with chronic obstructive pulmonary disease (COPD) and postbronchodilator ratio of forced expiratory volume in 1 s to forced vital capacity ≤ 0.70, receiving HH18 before study entry, were analysed (n=2784).

Interventions

Patients were ra

SUBMITTER: Dahl R 

PROVIDER: S-EPMC4710815 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature